ClinicalTrials.gg
CompletedNCT03596294Updated Oct 23, 2018

A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

A Phase 1 interventional study of Clazosentan and Rifampicin in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-23.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

A study in healthy male subjects to investigate whether administration of rifampicin can affect the fate in the body (amount and time of presence in the blood) of clazosentan

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the subject prior to any study-mandated procedure.
  • Healthy male subjects aged between 18 and 65 years (inclusive) at Screening.
  • (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at Screening.
  • Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and pulse rate 45-90 bpm (inclusive), measured on the same arm, after 5 min in the supine position at Screening and on Day -1 of the first Period.
  • Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests.

Study-specific criteria

  • Acceptance for the duration of the study and for 3 months thereafter to use a condom and not to procreate.

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to clazosentan.
  • Previous exposure to rifampicin within 3 months prior to Screening.
  • Known to clazosentan or rifampicin or treatments of the same class, or any of their .
  • Known hypersensitivity or allergy to natural rubber latex.
  • Participation in a clinical study involving study treatment administration within 3 months prior to Screening or in more than 4 clinical studies within 1 year prior to Screening.
  • History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to Screening.
  • Positive results for surface antigen or virus antibody at Screening.
  • Positive results from the serology at Screening.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Treatment sequence AB

    Period A: Saline + clazosentan Period B: Rifampicin + clazosentan

    Drug: Clazosentan · Drug: Rifampicin · Other: Saline (0.9% sodium chloride)

  • Experimental
    Treatment sequence BA

    Period B: Rifampicin + clazosentan Period A: Saline + clazosentan

    Drug: Clazosentan · Drug: Rifampicin · Other: Saline (0.9% sodium chloride)

Interventions

  • Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h

  • Single i.v. dose of 600 mg rifampicin for 30 min

  • OtherSaline (0.9% sodium chloride)

    Single i.v infusion of 500 mL saline for 30 min

06

What researchers measure

Primary outcomes

  1. AUC from zero to time t of the last measured concentration above the limit of quantification

    The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: 24 hours post treatment infusion initiation

  2. AUC from zero to infinity (AUC0-inf)

    The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: 24 hours post treatment infusion initiation

  3. AUC from zero to 3 h (AUC0-3)

    The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: 24 hours post treatment infusion initiation

  4. The maximum plasma concentration (Cmax)

    The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: 24 hours post treatment infusion initiation

  5. Terminal half-life (t½)

    The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: 24 hours post treatment infusion initiation

  6. Total body clearance (CL)

    The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: 24 hours post treatment infusion initiation

  7. Volume of distribution at steady state (Vss)

    The plasma PK parameters of clazosentan will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: 24 hours post treatment infusion initiation

07

Study locations

1 site
  • QPS Netherlands B.V.
    Groningen, 9713 GZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Aug 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2018
First posted
Jul 23, 2018
StartActual
Jul 19, 2018
Primary completionActual
Aug 3, 2018
CompletionActual
Aug 3, 2018
Last update
Oct 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03596294
Responsible party
Sponsor
First posted
Jul 23, 2018
Start date
Jul 19, 2018
Primary completion
Aug 3, 2018
Completion
Aug 3, 2018
Last update
Oct 23, 2018

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clazosentan · Rifampin

Start the discussion